155 related articles for article (PubMed ID: 35986169)
1. Development and validation of multivariate models integrating preoperative clinicopathological and radiographic findings to predict HER2 status in gastric cancer.
Xu M; Liu S; Li L; Qiao X; Ji C; Tan L; Zhou Z
Sci Rep; 2022 Aug; 12(1):14177. PubMed ID: 35986169
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of Multivariate Models Integrating Preoperative Clinicopathological Parameters and Radiographic Findings Based on Late Arterial Phase CT Images for Predicting Lymph Node Metastasis in Gastric Cancer.
Liu S; Qiao X; Xu M; Ji C; Li L; Zhou Z
Acad Radiol; 2021 Nov; 28 Suppl 1():S167-S178. PubMed ID: 33487536
[TBL] [Abstract][Full Text] [Related]
3. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
[TBL] [Abstract][Full Text] [Related]
4. Prediction of serosal invasion in gastric cancer: development and validation of multivariate models integrating preoperative clinicopathological features and radiographic findings based on late arterial phase CT images.
Liu S; Xu M; Qiao X; Ji C; Li L; Zhou Z
BMC Cancer; 2021 Sep; 21(1):1038. PubMed ID: 34530755
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of volume-based parameters using
Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
[TBL] [Abstract][Full Text] [Related]
6. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
7. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract][Full Text] [Related]
8. Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy.
Urabe M; Ushiku T; Seto Y; Fukayama M
Am J Surg Pathol; 2016 Oct; 40(10):1326-33. PubMed ID: 27259008
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
Jankowski C; Guiu S; Cortet M; Charon-Barra C; Desmoulins I; Lorgis V; Arnould L; Fumoleau P; Coudert B; Rouzier R; Coutant C; Reyal F
Breast Cancer Res Treat; 2017 Jan; 161(1):73-81. PubMed ID: 27807808
[TBL] [Abstract][Full Text] [Related]
10. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
[TBL] [Abstract][Full Text] [Related]
11. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis.
Wang HB; Liao XF; Zhang J
Medicine (Baltimore); 2017 Nov; 96(44):e8437. PubMed ID: 29095284
[TBL] [Abstract][Full Text] [Related]
13. Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment.
Xu C; Liu Y; Jiang D; Ge X; Huang J; Su J; Zhang X; Lu S; Ji Y; Hou J; Liu T; Hou Y
Aging (Albany NY); 2019 Nov; 11(22):10052-10060. PubMed ID: 31739285
[TBL] [Abstract][Full Text] [Related]
14. Construction of
Guo X; Zhou N; Chen Z; Liu T; Xu X; Lei X; Shen L; Gao J; Yang Z; Zhu H
Gastric Cancer; 2020 Jul; 23(4):614-626. PubMed ID: 31919745
[TBL] [Abstract][Full Text] [Related]
15. High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report.
Hu CT; Zhou YC; Zu LD; Fu GH; Li Q
Ann Palliat Med; 2021 May; 10(5):5846-5852. PubMed ID: 32921108
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
[TBL] [Abstract][Full Text] [Related]
17. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
An E; Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Liao WL; Cecchi F; Blackler A; Thyparambil S; Kim WH; Burrows J; Hembrough T; Catenacci DVT; Oh DY; Bang YJ
Ann Oncol; 2017 Jan; 28(1):110-115. PubMed ID: 27687309
[TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
Qin S; Ji J; Xu RH; Wang W; Tang Y; Bi F; Li J; Wang K; Xu JM; Fan Q; Su W; Shen L
Oncologist; 2021 Sep; 26(9):e1567-e1580. PubMed ID: 34003545
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
Yagi S; Wakatsuki T; Yamamoto N; Chin K; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Shinozaki E; Suenaga M; Fujisaki J; Ishikawa Y; Yamaguchi K; Namikawa K; Horiuchi Y
Gastric Cancer; 2019 May; 22(3):518-525. PubMed ID: 30328533
[TBL] [Abstract][Full Text] [Related]
20. Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
Mishima Y; Matsusaka S; Chin K; Mikuniya M; Minowa S; Takayama T; Shibata H; Kuniyoshi R; Ogura M; Terui Y; Mizunuma N; Hatake K
Target Oncol; 2017 Jun; 12(3):341-351. PubMed ID: 28508152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
